top of page

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

  • blonca9
  • Apr 1
  • 1 min read

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach.




Note: IDEA Pharma and Candel have a business relationship (as discussed).

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page